CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended		113 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
OPERATING EXPENSES
General and administrative	$ 1,169	$ 1,764	$ 32,655
Research and development	3,124	2,385	105,558
Purchased in-process research and development	0	0	34,311
Other	0	0	(375)
Total operating expenses	4,293	4,149	172,149
Interest and other income, net	(158)	(96)	(14,011)
Loss from continuing operations before taxes	4,135	4,053	158,138
Income tax benefit	(21)	0	(1,376)
Loss from continuing operations	4,114	4,053	156,762
Discontinued operations - net gain on sale of the bone device business, net of taxes of $267	0	0	(2,202)
Net Loss	4,114	4,053	154,560
Less: Net Loss attributable to the noncontrolling interest	(193)	(473)	(667)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 3,921	$ 3,580	$ 153,893
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.10	$ 0.09
Basic and diluted shares outstanding (in shares)	40,885	40,879